KINS vs NBIX · P/E 6.8, rev $125.6M vs P/E 45, rev $1.77B
Kingstone Companies Inc (KINS) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Kingstone Companies Inc (KINS) is a insurance - property & casualty company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported KINS revenue for 2026-06-30 was $125.6M. Net income was $9.7M. KINS currently screens at market cap $217.9M and trailing P/E 6.8.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
KINS currently screens at market cap $217.9M and trailing P/E 6.8. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the KINS and NBIX stock pages for the full models.
Not investment advice.